Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.06.2022 | Case report

Dasabuvir/ombitasvir/paritaprevir/ritonavir

Various toxicities: 5 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Huang YY, et al. Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. Therapeutic Drug Monitoring 44: 377-383, No. 3, Jun 2022. Available from: URL: http://doi.org/10.1097/FTD.0000000000000967 Huang YY, et al. Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. Therapeutic Drug Monitoring 44: 377-383, No. 3, Jun 2022. Available from: URL: http://​doi.​org/​10.​1097/​FTD.​0000000000000967​
Metadaten
Titel
Dasabuvir/ombitasvir/paritaprevir/ritonavir
Various toxicities: 5 case reports
Publikationsdatum
01.06.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-17465-4

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Tozinameran

Case report

Dexamethasone

Case report

Multiple Drugs